ClinicalTrials.gg
Active, not recruitingNCT03944772ORCHARDUpdated Jan 30, 2025

Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)

A Phase 2 interventional study of Osimertinib and Savolitinib in Non-Small Cell Lung Cancer, sponsored by AstraZeneca. Active, not recruiting at 47 sites in 9 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2025-01-30.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by May 2025, 1 year 6 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
247
Allocation
Non-randomized
Ages
18 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 90 studies testing osimertinib in Carcinoma, Non-Small-Cell Lung — 20 open to participants now, 43 under way, 8 of them phase 3. osimertinib · Carcinoma, Non-Small-Cell Lung.

Enrollment
13th of 90
247 · median 51
Started
2019
with 5 others
Phase 2
46 of 90
12 open now
Primary completion
2025-05
later than 13 of 42 live
Registered
47th of 90
by date
Lead sponsor
29 of 90
AstraZeneca

Among the 90 studies testing osimertinib in Carcinoma, Non-Small-Cell Lung, this one is the 13th largest by enrollment, is one of 6 that started in 2019, is one of 46 in phase 2, reaches primary completion later than 13 of the 42 other live ones, and was the 47th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

20 of the 90 studies testing osimertinib in Carcinoma, Non-Small-Cell Lung are open now, in 7 countries. Recruiting first, the newest first:

15 more — sign in →

By country, each count listing its studies:

All 20 open studies →

About osimertinib

osimertinib: first FDA approval 2015 (TAGRISSO), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 90 studies testing osimertinib in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

Phase 2 Platform Study in Patients with Advanced Non-Small Lung Cancer who progressed on First-Line Osimertinib Therapy. This study is modular in design, allowing evaluation of the efficacy, safety and tolerability of multiple study treatments.

Read the detailed description

This is an open-label, multicentre, multi-drug, biomarker-directed Phase 2 platform study in patients with advanced non-small cell lung cancer (NSCLC) harbouring an epidermal growth factor receptor (EGFR)-sensitizing mutation whose disease has progressed on first-line monotherapy with osimertinib.Treatment options for these patients are limited. Novel treatments for these patients are urgently required.

This study is modular in design, allowing evaluation of the efficacy, safety and tolerability of multiple study treatments.

03

Conditions studied

  • Non-Small Cell Lung Cancer

Keywords

  • Non-small cell lung cancer
  • NSCLC
  • tSCLC
  • NEC
  • Phase II
  • Platform study
  • Biomarker-directed
  • Durvalumab
  • Osimertinib
  • Savolitinib
  • Selumetinib
  • Etoposide
  • Gefitinib
  • Necitumumab
  • Platinum-containing doublet
  • Pemetrexed
  • EGFR positive
  • Carboplatin
  • Alectinib
  • Selpercatinib
  • Cisplatin
  • TKI-resistant
  • MET amplification
  • MET exon 14 skipping
  • EGFR
  • EGFR C797X
  • EGFR G724X
  • EGFR L718X
  • EGFR exon 20 insertion
  • EGFR amplification
  • BRAF V600E
  • ALK rearrangement
  • RET rearrangement
  • ROS1 rearrangement
  • NTRK fusion
  • KRAS G12C
  • Datopotamab deruxtecan
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion criteria applicable to all study treatment modules (Group A \& B)

  1. NSCLC with the following features:

    1. Locally advanced or disease (ie, advanced NSCLC) not amenable to curative surgery or radiotherapy at study entry.
    2. or cytologically confirmed adenocarcinoma of the lung (patients with mixed histology are eligible if adenocarcinoma is the predominant histology) harboring EGFR mutation(s) known to be associated with EGFR TKI sensitivity at diagnosis. Any histologically identifiable component of neuroendocrine transformation to SCLC or large cell NEC is required for treatment under Module 7.
    3. Received only one , with single-agent osimertinib, for advanced NSCLC, with clinical benefit as judged by investigator discretion.

      (Note: a 'line' of therapy is defined as a daily anti-cancer treatment administered for >14 days, or a single infusion of an intravenous anti-cancer treatment. For instance, patients who have had \<14 days of a first- or second- generation TKI prior to osimertinib, and stopped due to adverse events, would be eligible to enter this study, see also exclusion criteria 5).

      Patients previously treated adjuvantly or neo-adjuvantly are eligible per exclusion criterion 5.

    4. Evidence of radiological disease progression on first-line monotherapy with osimertinib 80 mg po QD.
  2. Suitable for a mandatory defined as having an accessible tumor; by whichever modality the site uses and, ideally, confirmed by the person who will perform the procedure; and a stable clinical condition that will allow the patient to tolerate the procedure. The biopsy should be performed within 60 days of the planned first dose of study treatment.
  3. Patients must have per 1.1, as defined by at least 1 lesion that can be accurately measured at baseline as ≥ 10 mm at the longest diameter (except lymph nodes which must have a short axis ≥ 15 mm) with computed tomography (CT) or magnetic resonance imaging (MRI), which is suitable for accurate repeated measurements. Previously irradiated lesions or a lesion in the field of radiation should not be used as measurable disease unless the lesion(s) has/have demonstrated unequivocal disease progression by RECIST 1.1. Target lesions should not be used for the baseline tumour biopsy, unless there are no other lesions suitable for biopsy and they fulfil requirements.
  4. Adequate coagulation parameters, defined as:

International Normalisation Ratio () \< 1.5 × (ULN) and activated partial thromboplastin time \< 1.5 × ULN unless patients are receiving therapeutic anti-coagulation which affects these parameters.

-------------------------------------------------------------------------------------------

Exclusion Criteria applicable to all study treatment modules (Groups A/B):

  1. Patients whose disease has progressed within the first 3 months of osimertinib treatment ( to osimertinib treatment).
  2. Patients must not have experienced a toxicity(-ies) that led to permanent discontinuation or dose reduction of prior osimertinib.

    (a) Patients who had dose reductions in the past, but were receiving a full dose of osimertinib at the time of pre-screening should be discussed with the Study Physician.

  3. Any unresolved toxicities from prior osimertinib treatment greater than Grade 1 at the time of starting study treatment.
  4. Patients should not have discontinued osimertinib >60 days prior to the first dose of study treatment.
  5. Inadequate bone marrow reserve or organ function as demonstrated by any of the following laboratory values:

    1. \< 1.5 × 109/L.
    2. count \< 100 × 109/L.
    3. \< 9 g/dL.
    4. (ALT) > 2.5 × ULN.
    5. Aspartate aminotransferase (AST) > 2.5 × ULN.
    6. Total (TBL) > 1.5 × ULN, or > 3 × ULN in the presence of documented Gilbert's Syndrome (unconjugated hyperbilirubinaemia).
  6. (CrCl) \< 50 mL/min, calculated using Cockcroft-Gault equation (Cockcroft and Gault 1976) or 24-hour urine collection. For medical conditions where the Cockcroft-Gault equation is inappropriate or 24-hour urine collection is unfeasible, CrCl may be calculated differently following written approval from the Study Physician.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
247 participants (actual)

Study arms

  • Experimental
    Module 1: Osimertinib + Savolitinib

    The patients in this group will receive osimertinib taken in combination with savolitinib

    Drug: Osimertinib · Drug: Savolitinib

  • Experimental
    Module 2: Osimertinib + Gefitinib

    The patients in this group will receive osimertinib taken in combination with gefitinib

    Drug: Osimertinib · Drug: Gefitinib

  • Experimental
    Module 3: Osimertinib + Necitumumab

    The patients in this group will receive osimertinib taken in combination with necitumumab

    Drug: Osimertinib · Drug: Necitumumab

  • Experimental
    Module 4: Carboplatin + Pemetrexed + Durvalumab)

    The patients in this group will receive platinum-containing doublet (carboplatin + pemetrexed) taken in combination with durvalumab.

    Drug: Durvalumab · Drug: Carboplatin · Drug: Pemetrexed

  • No intervention
    Observational Cohort: No study drug

    Patients in this group will not receive study treatment but receive further anticancer care (Standard of Care therapy or other experimental therapies) or supportive care, as clinically indicated, in accordance with local practice. With Group C, the aim is to understand the clinical course and/or outcome for the overall clinical population after progression on first-line monotherapy with osimertinib.

  • Experimental
    Module 5: Osimertinib + Alectinib

    The patients in this group will receive osimertinib taken in combination with alectinib

    Drug: Osimertinib · Drug: Alectinib

  • Experimental
    Module 6: Osimertinib + Selpercatinib

    The patients in this group will receive osimertinib taken in combination with selpercatinib

    Drug: Osimertinib · Drug: Selpercatinib

  • Experimental
    Module 7: Etoposide + Durvalumab + Carboplatin or Cisplatin

    The patients in this group will receive platinum-containing doublet (etoposide + carboplatin or cisplatin) taken in combination with durvalumab.

    Drug: Durvalumab · Drug: Carboplatin · Drug: Etoposide · Drug: Cisplatin

  • Experimental
    Module 8: Osimertinib + Pemetrexed + Carboplatin or Cisplatin.

    The patients in this group will receive Osimertinib plus platinum-containing doublet (pemetrexed + carboplatin or cisplatin).

    Drug: Osimertinib · Drug: Carboplatin · Drug: Pemetrexed · Drug: Cisplatin

  • Experimental
    Module 9: Osimertinib + Selumetinib

    The patients in this group will receive osimertinib taken in combination with selumetinib

    Drug: Osimertinib · Drug: Selumetinib

  • Experimental
    Module 10: Osimertinib + datopotamab deruxtecan

    The patients in this group will receive osimertinib taken in combination with datopotamab deruxtecan.

    Drug: Osimertinib · Drug: Datopotamab deruxtecan

Interventions

  • Osimertinib given orally at 80 mg once daily

    Also known as: TAGRISSO

  • Savolitinib will be given orally at 300 mg or 600mg once daily

  • Gefitinib given orally at 250 mg once daily

    Also known as: Iressa

  • Necitumumab given IV at 800 mg on Day 1 and Day 8 of every 3-week cycle

    Also known as: Portrazza

  • Durvalumab given IV at 1500 mg on Day 1 of every cycle

    Also known as: IMFINZI

  • Carboplatin given IV on Day 1 of every 21-day cycle for up to 6 cycles

  • Pemetrexed given IV at 500 mg/m2 body BSA on Day 1 of every cycle

  • Alectinib given orally at 600mg twice daily and for Japanese patients at 300mg twice daily.

    Also known as: Alecensa

  • Selpercatinib given orally at 160mg twice daily

    Also known as: Loxo-292, Retevmo, Retsevmo

  • Selumetinib given orally at 75 mg twice daily for 4 days, followed by 3 days off treatment

    Also known as: Koselugo

  • Etoposide 80-100 mg/m2 given IV on day 1, 2 and 3 of every 21-day cycle for up to 4 cycles.

  • Cisplatin 75-80 mg/m2 given IV on days 1 of each cycle

  • Datopotamab deruxtecan given IV at 4 or 6 mg/kg on Day 1 of every 3-week cycle.

    Also known as: DS 1062a

06

What researchers measure

Primary outcomes

  1. Objective response rate (ORR)

    The percentage of patients with a confirmed investigator-assessed complete or partial response according to Response Evaluation Criteria In Solid Tumours (RECIST) 1.1. Patients will be followed up every 6 weeks (±1 week) for the first 24 weeks and every 9 weeks thereafter until RECIST 1.1 defined disease progression or cessation of study treatment (if treating beyond progression).

    Time frame: Measured from first dose until confirmed response or progression. For each patient this is expected to be 3 months on average

Secondary outcomes

  1. Progression-free survival (PFS)

    The time from first dose until the date of objective disease progression or death (by any cause in the absence of progression). Patients will be followed up every 6 weeks (±1 week) for the first 24 weeks and every 9 weeks thereafter until RECIST (Response Evaluation Criteria In Solid Tumours)1.1 defined disease progression or cessation of study treatment (if treating beyond progression).

    Time frame: Measured from first dose until progression. For each patient this is expected to be 6 months on average

  2. Duration of response (DoR)

    The time from the date of first response until date of disease progression or death in the absence of disease progression. Patients will be followed up every 6 weeks (±1 week) for the first 24 weeks and every 9 weeks thereafter until RECIST 1.1 defined disease progression or cessation of study treatment (if treating beyond progression).

    Time frame: Measured from response until progression. For each patient this is expected to be 6 months on average

  3. Overall survival (OS)

    The time from the date of the first dose of study treatment until death due to any cause.

    Time frame: Measured from first dose until death or final cohort data cut-off. For each patient this is expected to be 20 months on average

  4. Plasma/serum concentrations of therapeutic agents

    Blood samples will be collected at various timepoints to evaluate the sparse pharmacokinetics of study therapeutic agents.

    Time frame: Pre-dose and 1 hour post-dose blood samples on Day 1 of Cycles 1, 3 (Cycle 2 for durvalumab), 6 for all therapeutic agents and a sample at the 90-day safety follow up for durvalumab only. (One Cycle = 21 or 28 days, depending on treatment).

  5. Plasma/serum concentrations of therapeutic agents

    Blood samples will be collected at various timepoints to evaluate the serial pharmacokinetics of study therapeutic agents

    Time frame: Pre-dose and serial post-dose blood samples (1 hour, 2 hours, 4 hours, 6 hours, 8 hours) on Day 15 of Cycle 1 for alectinib and selpercatinib only.

  6. Incidence of Treatment-emergent adverse events (AEs) and serious adverse events (SAEs) as characterized and graded by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Event [CTCAE] v5

    To evaluate safety and tolerability of each study treatment

    Time frame: Continuously from first dose to end of safety follow up after study treatment discontinuation (approximately up to 21 Months)

07

Study locations

47 sites
  • Research Site
    Duarte, California 91010, United States
  • Research Site
    Los Angeles, California 90048, United States
  • Research Site
    Sacramento, California 95817, United States
  • Research Site
    Santa Monica, California 90404, United States
  • Research Site
    New Haven, Connecticut 06510, United States
  • Research Site
    Chicago, Illinois 60612, United States
  • Research Site
    Baltimore, Maryland 21224, United States
  • Research Site
    Boston, Massachusetts 02114, United States
  • Research Site
    Boston, Massachusetts 02215, United States
  • Research Site
    Grand Rapids, Michigan 49503, United States
  • Research Site
    New York, New York 10017, United States
  • Research Site
    New York, New York 10032, United States
  • Research Site
    Portland, Oregon 97239, United States
  • Research Site
    Pittsburgh, Pennsylvania 15232, United States
  • Research Site
    Houston, Texas 77030, United States
  • Research Site
    Seattle, Washington 98109, United States
  • Research Site
    Odense C, 5000, Denmark
  • Research Site
    Catania, 95123, Italy
  • Research Site
    Napoli, 80131, Italy
  • Research Site
    Orbassano, 10043, Italy
  • Research Site
    Padova, 35128, Italy
  • Research Site
    Varese, 21100, Italy
  • Research Site
    Chuo-ku, 104-0045, Japan
  • Research Site
    Fukuoka-shi, 812-8582, Japan
  • Research Site
    Koto-ku, 135-8550, Japan
  • Research Site
    Nagoya-shi, 464-8681, Japan
  • Research Site
    Osaka-shi, 541-8567, Japan
  • Research Site
    Wakayama-shi, 641-8510, Japan
  • Research Site
    Seongnam-si, 13620, Korea, Republic of
  • Research Site
    Seoul, 03722, Korea, Republic of
  • Research Site
    Seoul, 05505, Korea, Republic of
  • Research Site
    Seoul, 06351, Korea, Republic of
  • Research Site
    Amsterdam, 1066 CX, Netherlands
  • Research Site
    Amsterdam, 1081 HV, Netherlands
  • Research Site
    Maastricht, 6229 HX, Netherlands
  • Research Site
    Nijmegen, 6525 GA, Netherlands
  • Research Site
    Rotterdam, 3015GD, Netherlands
  • Research Site
    Drammen, 3004, Norway
  • Research Site
    Oslo, N-0310, Norway
  • Research Site
    Trondheim, 7030, Norway
  • Research Site
    A Coruña, 15006, Spain
  • Research Site
    Barcelona, 08025, Spain
  • Research Site
    Barcelona, 08036, Spain
  • Research Site
    Madrid, 28041, Spain
  • Research Site
    Madrid, 28046, Spain
  • Research Site
    Sevilla, 41009, Spain
  • Research Site
    Stockholm, 17176, Sweden
08

References and documents

Publications

  • Yu HA, Goldberg SB, Le X, Piotrowska Z, Goldman JW, De Langen AJ, Okamoto I, Cho BC, Smith P, Mensi I, Ambrose H, Kraljevic S, Maidment J, Chmielecki J, Li-Sucholeiki X, Doughton G, Patel G, Jewsbury P, Szekeres P, Riess JW. Biomarker-Directed Phase II Platform Study in Patients With EGFR Sensitizing Mutation-Positive Advanced/Metastatic Non-Small Cell Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy (ORCHARD). Clin Lung Cancer. 2021 Nov;22(6):601-606. doi: 10.1016/j.cllc.2021.06.006. Epub 2021 Jun 25. PubMed 34389237 ↗
  • Schmid S, Fruh M, Peters S. Targeting MET in EGFR resistance in non-small-cell lung cancer-ready for daily practice? Lancet Oncol. 2020 Mar;21(3):320-322. doi: 10.1016/S1470-2045(19)30859-9. Epub 2020 Feb 3. No abstract available. PubMed 32027845 ↗

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2019 (actual). Primary completion is estimated for May 2025, 70 months after the start.

Of 317 industry-sponsored phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's planned 70 months is above that.

Counting every sponsor, half of 1,047 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 29, 2019
First posted
May 10, 2019
StartActual
Jun 25, 2019
Primary completionEst.
May 6, 2025
CompletionEst.
May 6, 2025
Last update
Jan 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03944772
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
May 10, 2019
Start date
Jun 25, 2019
Primary completion
May 6, 2025 (estimated)
Completion
May 6, 2025 (estimated)
Last update
Jan 30, 2025

Study contacts

Helena A Yu, MD
principal investigator · Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Osimertinib · Durvalumab · Carboplatin · Pemetrexed · Etoposide · Cisplatin · Datopotamab deruxtecan

Start the discussion